AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II


Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Upside 195%
Price (€) 3.93
Market Cap (€M) 144
Perf. 1W: 2.08%
Perf. 1M: -6.87%
Perf. 3M: 3.01%
Perf Ytd: 19.3%
10 day relative perf. to stoxx600: 1.53%
20 day relative perf. to stoxx600: -5.48%
Financing issue 06/04/2017

The capital increase was successful


The capital increase was 137% subscribed, raising the group equity by some €4.98m gross after the exercise of the 15% extension clause.


As a reminder, the capital increase was carried out from 16 to 30 March at €4.5 per share. As a result of this successful operation, the number of shares will rise by 1.107m (to be listed as of 7 April) to 8,813m. The company will also have enough cash to finance the next two financial years, even before partnerships and tax credits (CIR).


We will fine-tune our numbers, based on the outcome of the capital increase, but this will only be marginal since we have already taken into account this new issue.


05 Sep 18 Target Change
On its way to reaching the market

17 May 18 Latest
Business update

22 Mar 18 Earnings/sales releases
On its way to reach the market…

03 Feb 18 Other news/comments
Orphan disease status for Zeneo® Midazolam i...

11 Dec 17 Other news/comments
Update on the company’s activities

25 Sep 17 Earnings/sales releases
H1 17: a new NTE in the pipeline...and further d...

06 Apr 17 Financing issue
The capital increase was successful